miR-155 harnesses Phf19 to potentiate cancer immunotherapy through epigenetic reprogramming of CD8+ T cell fate

miR-155 harnesses Phf19 to potentiate cancer immunotherapy through epigenetic reprogramming of CD8+ T cell fate

The inability of T cells to properly mount anti-tumour immunity underlies failed cancer immune surveillance or therapy. Here the authors show that a microRNA, miR-155, suppresses Ship1 phosphatase expression to modulate epigenetic reprogramming of CD8 T cell differentiation via the Phf19/PRC2 axis,...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Yun Ji, Jessica Fioravanti, Wei Zhu, Hongjun Wang, Tuoqi Wu, Jinhui Hu, Neal E. Lacey, Sanjivan Gautam, John B. Le Gall, Xia Yang, James D. Hocker, Thelma M. Escobar, Shan He, Stefania Dell’Orso, Nga V. Hawk, Veena Kapoor, William G. Telford, Luciano Di Croce, Stefan A. Muljo, Yi Zhang, Vittorio Sartorelli, Luca Gattinoni
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2019
Materias:
Science
Q
Acceso en línea:https://doaj.org/article/f7106871939f484092d79cd389893db3
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:The inability of T cells to properly mount anti-tumour immunity underlies failed cancer immune surveillance or therapy. Here the authors show that a microRNA, miR-155, suppresses Ship1 phosphatase expression to modulate epigenetic reprogramming of CD8 T cell differentiation via the Phf19/PRC2 axis, thereby implicating a novel aspect of cancer immunity regulation.

Ejemplares similares